Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with …
B Chua, EH Tan, DWT Lim, MK Ang… - Annals of …, 2018 - annalsofoncology.org
Background: Treatment options for EGFR mutant advanced/metastatic NSCLC patients
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
[HTML][HTML] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
I Okamoto, S Morita, N Tashiro, F Imamura, A Inoue… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase …
SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized …
CM Zhu, XY Lian, HY Zhang, L Bai… - Journal of Cancer …, 2021 - journals.lww.com
Objective: The objective of this study was to perform a meta-analysis comparing the
efficiency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with …
efficiency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with …
[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
[HTML][HTML] Comparison of outcomes of tyrosine kinase inhibitor in first-or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR …
J Xu, X Zhang, H Yang, G Ding, B Jin, Y Lou, Y Zhang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Direct comparisons between the use of first-and second-line EGFR tyrosine kinase inhibitor
(TKI) in patients with sensitive EGFR mutations are limited. A total of 264 advanced non …
(TKI) in patients with sensitive EGFR mutations are limited. A total of 264 advanced non …
Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
CY Lin, CH Hu, CF Hsu, JS Tsai, CW Chen… - Thoracic …, 2023 - Wiley Online Library
Background Some prospective studies have shown that second‐generation tyrosine kinase
inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) …
inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) …
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR …
HA Jung, S Park, JM Sun, SH Lee, JS Ahn, MJ Ahn… - Biology, 2020 - mdpi.com
Simple Summary The present study showed the comprehensive analysis of disease
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …
Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first-line, first-or second-generation EGFR tyrosine kinase inhibitor in South …
JC Lee, JY Hung, YC Kim, GC Chang, SS Yoo… - Asian Pacific Journal of …, 2021 - waocp.com
Introduction: The preferred first-line (1L) treatment for epidermal growth factor receptor
(EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) …
(EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) …
相关搜索
- egfr mutations meta analysis
- egfr mutations lung cancer
- egfr mutations nsclc patients
- lung cancer meta analysis
- lung cancer combination with chemotherapy
- chemotherapy outcomes egfr tki
- egfr mutations combination with chemotherapy
- nsclc patients meta analysis
- egfr mutations comparison of outcomes
- chemotherapy outcomes egfr mutation